Phosphorus binder
Pro Research Analysisby 
Searched over 200M research papers for "phosphorus binder"
Phosphorus Binders in Chronic Kidney Disease: Efficacy and Safety
Introduction to Phosphorus Binders
Phosphorus binders are essential in managing hyperphosphatemia in patients with chronic kidney disease (CKD), particularly those undergoing dialysis. These agents help control serum phosphorus levels by binding dietary phosphorus in the gastrointestinal tract, thereby reducing its absorption. This article synthesizes recent research on various phosphorus binders, focusing on their efficacy, safety, and comparative performance.
Efficacy of Different Phosphorus Binders
Calcium-Based Binders
Calcium-based binders, such as calcium acetate and calcium carbonate, are commonly used due to their effectiveness in reducing serum phosphorus levels. However, they are associated with an increased risk of hypercalcemia, which can limit their use, especially in patients treated with calcitriol 16. Studies have shown that calcium acetate is more efficient than calcium carbonate in inhibiting dietary phosphorus absorption .
Non-Calcium-Based Binders
Ferric Citrate
Ferric citrate is an iron-based binder that effectively lowers serum phosphorus levels. A randomized clinical trial demonstrated that ferric citrate provides similar phosphorus control compared to sevelamer carbonate and calcium acetate, with a comparable safety profile and fewer serious adverse events . Additionally, ferric citrate has been shown to increase serum bicarbonate levels, which can be beneficial in managing metabolic acidosis in CKD patients .
Sevelamer
Sevelamer, a non-calcium, non-metal binder, has been shown to reduce the risk of all-cause mortality compared to calcium-based binders . However, it is associated with a higher incidence of gastrointestinal adverse events 34. Sevelamer also significantly decreases serum calcium levels, which can be advantageous in preventing hypercalcemia .
Lanthanum Carbonate
Lanthanum carbonate is another non-calcium binder that effectively controls serum phosphorus levels. It has been found to attenuate the progression of coronary artery calcification compared to calcium-based binders . However, like sevelamer, it is associated with gastrointestinal side effects .
Magnesium Carbonate
Magnesium carbonate has been studied as an alternative to calcium-based binders. It allows for a reduction in the dose of calcium carbonate while maintaining acceptable levels of serum calcium, phosphorus, and magnesium. This can facilitate the use of higher doses of calcitriol without causing hypercalcemia .
Novel Binders
RenaGel (Sevelamer Hydrochloride)
RenaGel, a non-absorbable polymeric binder, has shown efficacy in reducing urinary phosphorus excretion and increasing fecal phosphorus excretion in both human and animal studies 710. It is well-tolerated and does not contain calcium or aluminum, making it a safer alternative for long-term use .
Safety and Adverse Effects
Hypercalcemia and Vascular Calcification
Calcium-based binders are effective but pose a risk of hypercalcemia, which can lead to vascular calcification. Non-calcium binders like sevelamer and lanthanum carbonate are preferred in patients at risk of hypercalcemia 45. However, phosphate binders, in general, have been associated with increased vascular calcification, highlighting the need for careful monitoring .
Gastrointestinal Side Effects
Non-calcium binders, particularly sevelamer and lanthanum, are associated with a higher incidence of gastrointestinal adverse events compared to calcium-based binders 34. This can affect patient compliance and overall treatment efficacy.
Conclusion
Phosphorus binders play a crucial role in managing hyperphosphatemia in CKD patients. While calcium-based binders are effective, their use is limited by the risk of hypercalcemia. Non-calcium binders like ferric citrate, sevelamer, and lanthanum carbonate offer effective alternatives with different safety profiles. Novel binders such as RenaGel provide additional options, particularly for patients who cannot tolerate traditional binders. Ongoing research and individualized patient management are essential to optimize treatment outcomes and minimize adverse effects.
Sources and full results
Most relevant research papers on this topic
Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study.
Calcium acetate and aluminum carbonate gel are more efficient and less toxic than calcium carbonate and calcium citrate in inhibiting dietary phosphorus absorption in normal subjects.
#3775 PHOSPHATE BINDERS FOR PATIENTS WITH CHRONIC KIDNEY DISEASE UNDERGOING DIALYSIS: A NETWORK META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS
Sevelamer reduces all-cause mortality in chronic kidney disease patients, while lanthanum may slow coronary artery calcium progression.
Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
There is insufficient data to compare non-calcium-binding agents to calcium-containing phosphate binders for important patient-level outcomes like all-cause mortality and cardiovascular end points.
Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study.
Magnesium carbonate (MgCO3) can reduce the dose of calcium carbonate in chronic hemodialysis patients, potentially allowing larger doses of calcitriol without causing hypercalcemia.
RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers.
RenaGel is a safe, effective, and well-tolerated phosphate binder in normal volunteers, potentially benefiting renal failure patients.
DOI
An Update on Phosphate Binders: A Dietitian's Perspective.
Phosphate binders are a safe and effective treatment for hyperphosphatemia in chronic kidney disease patients on dialysis, with newer compounds offering better pharmacokinetics, side effects, and a new calculation for comparing their effectiveness.
DOI
Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats.
RenaGel is a potent phosphate binder that effectively reduces urinary phosphorus excretion in rats without causing side effects or toxicities, offering an alternative to existing treatments.
DOI